Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population

Choi, Debra T.; Puenpatom, Amy; Xin, Yu; Erickson, Kevin F.; Kanwal, Fasiha; El–Serag, Hashem B.; Kramer, Jennifer R.

doi:10.1016/j.antiviral.2019.104698

Cited by 10 publications

(5 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Glecaprevir/pibrentasvir and grazoprevir/elbasvir have been separately analyzed in different real-life cohorts in the past and have shown excellent effectiveness and tolerability in patients with chronic hepatitis C and stage 4 or 5 CKD [14][15][16][17][18]. Our data are in line with the results of the previous studies.…”

Section: Discussionsupporting

confidence: 87%

“…Controlled clinical studies have shown excellent safety and efficacy in patients with severe renal impairment which led to marketing authorization for this population [12,13]. Post-marketing real-life experience with grazoprevir/elbasvir in advanced CKD cases has been described in several Asian and Caucasian cohorts [14][15][16][17][18], while comparable data of glecaprevir/ pibrentasvir is limited to a cohort from Taiwan so far [19]. All these reports have analyzed the two antiviral treatment options separately, a direct comparison has not been performed so far.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R)

Stein¹,

Stoehr

Klinker

et al. 2020

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

Objectives Grazoprevir/elbasvir and glecaprevir/pibrentasvir (G/P) are the two preferred treatment options for patients with chronic hepatitis C virus (HCV) infection and a glomerular filtration rate (GFR) <30 mL/min. Both therapies have been separately analyzed in different real-life cohorts; however, a direct comparison has not been performed so far. We, therefore, analyzed safety and effectiveness of both regimens in a concerted real-life population. Methods The Germany Hepatitis C-Registry is a prospective national real-world registry. The analysis is based on 2773 patients with documented GFR at baseline treated with grazoprevir/elbasvir (N = 1041), grazoprevir/elbasvir + ribavirin (N = 53) and glecaprevir/pibrentasvir (N = 1679). Results A total of 93 patients with GFR <30 mL/min were treated with grazoprevir/elbasvir (N = 56), grazoprevir/ elbasvir + ribavirin (N = 4), and glecaprevir/pibrentasvir (N = 33). They suffered significantly more frequent from diabetes mellitus, hypertension, and coronary heart disease than individuals with GFR >30 mL/min and showed the following baseline characteristics: 20.4, 55.9, 3.2, 12.9, and 5.3% were infected with HCV-genotypes 1a, 1b, 2, 3, and 4; 12.9% suffered from liver cirrhosis; 80.1% were treatment-naïve. Baseline characteristics except distribution of HCV-genotype 1b (n = 43/52 treated with grazoprevir/elbasvir) and sustained virologic response rates (SVR12) did not differ significantly between glecaprevir/ pibrentasvir (SVR12: 100%) and grazoprevir/elbasvir (SVR12: 97.9%). Fatigue, headache, abdominal discomfort, and arthralgia were the most frequently reported adverse events without a statistical difference between grazoprevir/elbasvir and glecaprevir/pibrentasvir. Conclusion In patients with chronic hepatitis C and a baseline GFR ≤30 mL/min grazoprevir/elbasvir and glecaprevir/ pibrentasvir show an equally favorable safety profile and antiviral efficacy and can both be recommended for real-life use. Eur

show abstract

Section: Discussionsupporting

confidence: 87%

Section: Introductionmentioning

confidence: 99%

Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R)

Stein¹,

Stoehr

Klinker

et al. 2020

European Journal of Gastroenterology &Amp; Hepatology

View full text Add to dashboard Cite

show abstract

“…We found 22 studies that reported on specific DAA regimens in patients with CKD G4–G5ND (eGFR <30 ml/min per 1.73 m 2 , not on dialysis). 9 , 21 , 22 , 23 , 24 , 25 , 26 , 27 , 28 , 29 , 30 , 31 , 32 , 33 , 34 , 35 , 36 , 37 , 38 , 39 , 40 , 41 The studies evaluated the following: DCV/ASV (1 study, N = 10), GLE/PIB (4 studies, N = 149), GZR/EBR (5 studies, N = 857), PrO±D (5 studies, N = 153), SOF (2 studies, N = 41), SOF/DCV (4 studies, N = 571), SOF/LDV (2 studies, N = 43), SOF/SIM (1 study, N = 41), and SOF/VEL (2 studies, N = 99). Conclusions pertaining to DAA treatment in patients in CKD G4–G5ND are summarized in Table 1 .…”

Section: Ckd G4–g5ndmentioning

confidence: 99%

“…Across 3817 patients, only 35 were on peritoneal dialysis. 9 , 22 , 23 , 24 , 26 , 29 , 30 , 31 , 34 , 37 , 38 , 39 , 42 , 43 , 44 , 45 , 46 , 47 , 48 , 49 , 50 , 51 , 52 , 53 , 54 , 55 , 56 , 57 , 58 , 59 , 60 , 61 , 62 , 63 , 64 , 65 , 66 , 67 , 68 , 69 , 70 , 71 , 72 , 73 , 74 , 75 , 76 , 77 , 78 , 79 , 80 , 81 , 82 , 83 , 84 , 85 , 86 , 87 , 88 , 89 , 90 , 91 , 92 , 93 , 94 , 95 , 96 , 97 , 98 The s...…”

Section: Ckd G4–g5ndunclassified

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

Balk¹,

Adam²,

Jadoul³

et al. 2023

Kidney International Reports

View full text Add to dashboard Cite

“…Elbasvir/grazoprevir (EBR/GZR) is a fixed-dose combination treatment for HCV genotype 1 or 4 infection. The efficacy and safety of EBR/GZR in CKD patients, including those on HD, has been reported in studies [7][8][9][10]. However, to our knowledge, there are no reports on EBR/GZR use in HCV-infected PD patients.…”

mentioning

confidence: 96%

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient

Chen

et al. 2020

Renal Failure

View full text Add to dashboard Cite

Hepatitis C virus (HCV) infection is known to affect long-term patient survivals. Elbasvir/grazoprevir (EBR/GZR) has shown a high cure rate in hemodialysis patients with HCV infection. However, the combination is rarely used in peritoneal dialysis patients. Herein, we report a case of successful treatment with EBR/GZR in a peritoneal dialysis patient with HCV genotype 1 b infection. A 54-year-old woman on peritoneal dialysis(PD) with HCV genotype 1 b infection had been received EBR (100 mg) and GZR (50 mg) once daily for 12 weeks. Hepatitis C virus RNA was undetectable 4 weeks after the treatment. She achieved a sustained virological response at 12 weeks after the end of treatment. Only fatigue was reported as side effect during the treatment. Thus, elbasvir/grazoprevir was effective and safe in this PD patient with HCV genotype 1 b infection.

show abstract

Effectiveness of Elbasvir/Grazoprevir in patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States veterans population

Cited by 10 publications

References 23 publications

Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R)

Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R)

A Systematic Review of Direct-Acting Antivirals for Hepatitis C in Advanced CKD

Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient

Contact Info

Product

Resources

About